Farmakis Dimitrios, Stafylas Panagiotis, Giamouzis Gregory, Maniadakis Nikolaos, Parissis John
Department of Cardiology, Athens University Hospital Attikon, Athens, Greece.
Medical Research & Innovation LP, Thessaloniki, Greece.
Int J Cardiol. 2016 Jan 15;203:279-81. doi: 10.1016/j.ijcard.2015.10.172. Epub 2015 Oct 20.
Cardiovascular disease and cancer represent the two leading causes of death in the Western World. Still, cardiovascular disease causes more deaths and more hospitalizations than cancer. Although mortality rates of both conditions are generally declining, this is not true for heart failure (HF). The prevalence of HF is increasing, although its incidence has been stabilized, mainly because of the population aging. The survival of patients with HF is overall worse than those with cancer. In addition, HF failure is the most common reason for hospitalization in the elderly, while hospitalization for HF is followed by adverse prognosis and represents the main contributor to the huge financial expenditure caused by the syndrome. The outcome of HF patients and thus its medical and socioeconomic burden may be improved by the more efficient in-hospital management of patients, the enhancement of adherence to guideline-recommended therapies, the identification and treatment of comorbid conditions and the introduction of more effective medical therapies.
心血管疾病和癌症是西方世界两大主要死因。尽管如此,心血管疾病导致的死亡和住院人数仍多于癌症。虽然这两种疾病的死亡率总体上都在下降,但心力衰竭(HF)并非如此。HF的患病率在上升,尽管其发病率已趋于稳定,主要原因是人口老龄化。HF患者的总体生存率低于癌症患者。此外,HF是老年人住院最常见的原因,而HF住院后的预后较差,是该综合征造成巨额财政支出的主要因素。通过更高效地管理住院患者、加强对指南推荐疗法的依从性、识别和治疗合并症以及引入更有效的药物治疗,可以改善HF患者的预后,从而减轻其医疗和社会经济负担。